Critical Path Institute is pleased to announce the recent collaboration agreement between C-Path and Mobilise-D. By combining C-Path’s unique global regulatory expertise and Mobilise-D’s focus on digital assessment of mobility, this mutually beneficial partnership aims to accelerate and improve the impact of these important initiatives that share common goals. The Critical Path for Parkinson’s consortium is uniquely positioned to collaborate with Mobilise-D, thanks to its Digital Drug Development Tool (3DT) initiative combined with its EMA and FDA experiences. Alliances with Mobilise-D promise to enable efficiencies in advancing digital health technologies for clinical trials through enhanced communication and long lasting collaborations across the globe.
